Microsporidiosis secondary prevention

Microsporidiosis Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Microsporidiosis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory findings
X ray
CT
MRI
Other imaging studies
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Microsporidiosis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Microsporidiosis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Microsporidiosis secondary prevention
CDC on Microsporidiosis secondary prevention
Microsporidiosis secondary prevention in the news
Blogs on Microsporidiosis secondary prevention
Directions to Hospitals Treating Microsporidiosis
Risk calculators and risk factors for Microsporidiosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2]

Overview

Secondary prevention strategies following microsporidiosis include continuing treatment indefinitely after ocular microsporidiosis and continued HAART for HIV patients.

Secondary Prevention

The following measures are effective for preventing recurrence:

• Treatment for ocular microsporidiosis should be continued indefinitely because recurrence or relapse might follow treatment discontinuation (BIII).
• Whether treatment can be safely discontinued after immune restoration with antiretroviral therapy (ART) is unknown, although it is reasonable, on the basis of the experience with discontinuation of secondary prophylaxis (chronic maintenance therapy) for other opportunistic infections during advanced HIV-1 disease, to discontinue chronic maintenance therapy if patients remain asymptomatic with regard to signs and symptoms of microsporidiosis and have a sustained (e.g. >6 months) increase in their CD4⁺ T lymphocyte counts to levels >200 cells/µL after ART (CIII).